Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Acronyms alleviate 1
- Sponsors Novo Nordisk
- 31 Jan 2017 Status changed from not yet recruiting to recruiting.
- 30 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2017.
- 27 Oct 2016 New trial record